Cargando…

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convalescent blood donors in addition to 15 naive individuals, as well as an...

Descripción completa

Detalles Bibliográficos
Autores principales: Natarajan, Harini, Crowley, Andrew R., Butler, Savannah E., Xu, Shiwei, Weiner, Joshua A., Bloch, Evan M., Littlefield, Kirsten, Wieland-Alter, Wendy, Connor, Ruth I., Wright, Peter F., Benner, Sarah E., Bonny, Tania S., Laeyendecker, Oliver, Sullivan, David, Shoham, Shmuel, Quinn, Thomas C., Larman, H. Benjamin, Casadevall, Arturo, Pekosz, Andrew, Redd, Andrew D., Tobian, Aaron A. R., Ackerman, Margaret E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092262/
https://www.ncbi.nlm.nih.gov/pubmed/33879585
http://dx.doi.org/10.1128/mBio.00765-21
_version_ 1783687624583544832
author Natarajan, Harini
Crowley, Andrew R.
Butler, Savannah E.
Xu, Shiwei
Weiner, Joshua A.
Bloch, Evan M.
Littlefield, Kirsten
Wieland-Alter, Wendy
Connor, Ruth I.
Wright, Peter F.
Benner, Sarah E.
Bonny, Tania S.
Laeyendecker, Oliver
Sullivan, David
Shoham, Shmuel
Quinn, Thomas C.
Larman, H. Benjamin
Casadevall, Arturo
Pekosz, Andrew
Redd, Andrew D.
Tobian, Aaron A. R.
Ackerman, Margaret E.
author_facet Natarajan, Harini
Crowley, Andrew R.
Butler, Savannah E.
Xu, Shiwei
Weiner, Joshua A.
Bloch, Evan M.
Littlefield, Kirsten
Wieland-Alter, Wendy
Connor, Ruth I.
Wright, Peter F.
Benner, Sarah E.
Bonny, Tania S.
Laeyendecker, Oliver
Sullivan, David
Shoham, Shmuel
Quinn, Thomas C.
Larman, H. Benjamin
Casadevall, Arturo
Pekosz, Andrew
Redd, Andrew D.
Tobian, Aaron A. R.
Ackerman, Margaret E.
author_sort Natarajan, Harini
collection PubMed
description Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convalescent blood donors in addition to 15 naive individuals, as well as an additional 20 convalescent individuals as a validation cohort. Multiplexed Fc Array binding assays and functional antibody response assays were utilized to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody composition and activity. Donor convalescent plasma samples contained a range of antibody cell- and complement-mediated effector functions, indicating the diverse antiviral activity of humoral responses observed among recovered individuals. In addition to viral neutralization, convalescent plasma samples contained antibodies capable of mediating such Fc-dependent functions as complement activation, phagocytosis, and antibody-dependent cellular cytotoxicity against SARS-CoV-2. Plasma samples from a fraction of eligible donors exhibited high activity across all activities evaluated. These polyfunctional plasma samples could be identified with high accuracy with even single Fc Array features, whose correlation with polyfunctional activity was confirmed in the validation cohort. Collectively, these results expand understanding of the diversity of antibody-mediated antiviral functions associated with convalescent plasma, and the polyfunctional antiviral functions suggest that it could retain activity even when its neutralizing capacity is reduced by mutations in variant SARS-CoV-2.
format Online
Article
Text
id pubmed-8092262
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-80922622021-05-04 Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma Natarajan, Harini Crowley, Andrew R. Butler, Savannah E. Xu, Shiwei Weiner, Joshua A. Bloch, Evan M. Littlefield, Kirsten Wieland-Alter, Wendy Connor, Ruth I. Wright, Peter F. Benner, Sarah E. Bonny, Tania S. Laeyendecker, Oliver Sullivan, David Shoham, Shmuel Quinn, Thomas C. Larman, H. Benjamin Casadevall, Arturo Pekosz, Andrew Redd, Andrew D. Tobian, Aaron A. R. Ackerman, Margaret E. mBio Research Article Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convalescent blood donors in addition to 15 naive individuals, as well as an additional 20 convalescent individuals as a validation cohort. Multiplexed Fc Array binding assays and functional antibody response assays were utilized to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody composition and activity. Donor convalescent plasma samples contained a range of antibody cell- and complement-mediated effector functions, indicating the diverse antiviral activity of humoral responses observed among recovered individuals. In addition to viral neutralization, convalescent plasma samples contained antibodies capable of mediating such Fc-dependent functions as complement activation, phagocytosis, and antibody-dependent cellular cytotoxicity against SARS-CoV-2. Plasma samples from a fraction of eligible donors exhibited high activity across all activities evaluated. These polyfunctional plasma samples could be identified with high accuracy with even single Fc Array features, whose correlation with polyfunctional activity was confirmed in the validation cohort. Collectively, these results expand understanding of the diversity of antibody-mediated antiviral functions associated with convalescent plasma, and the polyfunctional antiviral functions suggest that it could retain activity even when its neutralizing capacity is reduced by mutations in variant SARS-CoV-2. American Society for Microbiology 2021-04-20 /pmc/articles/PMC8092262/ /pubmed/33879585 http://dx.doi.org/10.1128/mBio.00765-21 Text en Copyright © 2021 Natarajan et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Natarajan, Harini
Crowley, Andrew R.
Butler, Savannah E.
Xu, Shiwei
Weiner, Joshua A.
Bloch, Evan M.
Littlefield, Kirsten
Wieland-Alter, Wendy
Connor, Ruth I.
Wright, Peter F.
Benner, Sarah E.
Bonny, Tania S.
Laeyendecker, Oliver
Sullivan, David
Shoham, Shmuel
Quinn, Thomas C.
Larman, H. Benjamin
Casadevall, Arturo
Pekosz, Andrew
Redd, Andrew D.
Tobian, Aaron A. R.
Ackerman, Margaret E.
Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
title Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
title_full Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
title_fullStr Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
title_full_unstemmed Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
title_short Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
title_sort markers of polyfunctional sars-cov-2 antibodies in convalescent plasma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092262/
https://www.ncbi.nlm.nih.gov/pubmed/33879585
http://dx.doi.org/10.1128/mBio.00765-21
work_keys_str_mv AT natarajanharini markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT crowleyandrewr markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT butlersavannahe markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT xushiwei markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT weinerjoshuaa markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT blochevanm markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT littlefieldkirsten markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT wielandalterwendy markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT connorruthi markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT wrightpeterf markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT bennersarahe markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT bonnytanias markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT laeyendeckeroliver markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT sullivandavid markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT shohamshmuel markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT quinnthomasc markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT larmanhbenjamin markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT casadevallarturo markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT pekoszandrew markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT reddandrewd markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT tobianaaronar markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma
AT ackermanmargarete markersofpolyfunctionalsarscov2antibodiesinconvalescentplasma